VRAX
Virax Biolabs Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$2.63
+2.54%Margins
Gross margin
-1280.8%
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-177.2%
Return on equity
-161.3%
Return on assets
-189.5%
Return on invested capital
0.00x
Asset turnover
-$12.1M
Cash from operations
$8.18
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026